Skip to main content

Table 1 Baseline patient characteristics, stratified by disease duration

From: Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials

Variable

All patients (n = 93)

Placebo (n = 48)

CYC (n = 45)

p Value

Age, yr, mean (SD)

47.19 (11.72)

47.43 (13.24)

46.93 (10.00)

0.8388

Female sex, n (%)

68 (73.12)

34 (70.83)

34 (75.56)

0.6077

White race, n (%)

71 (76.34)

38 (79.17)

33 (73.33)

0.6764

Type of SSc, n (%)

    

 Limited

37 (39.78)

19 (39.58)

18 (40.00)

0.9673

 Diffuse

56 (60.22)

29 (60.42)

27 (60.00)

 

Disease duration, yr, mean (SD)

3.27 (2.24)

3.30 (1.97)

3.24 (2.52)

0.8895

Antibodies (n = 55), n (%)a

    

 Scl-70

22 (32.84)

13 (35.14)

9 (30.00)

0.6563

 Anti-centromere/anti-RNA polymerase III

14 (20.90)

5 (13.51)

9 (30.00)

0.0988

FVC, % predicted, mean (SD)

67.73 (11.90)

68.86 (11.91)

66.53 (11.90)

0.3497

DLCO, % predicted, mean (SD)

46.32 (12.75)

46.04 (12.41)

46.61 (13.24)

0.8303

MRSS, mean (SD)

15.22 (11.02)

14.56 (10.52)

15.91 (11.60)

0.5580

Mahler’s BDI focal score (0–12), mean (SD)

5.67 (1.76)

5.48 (1.99)

5.90 (1.45)

0.2613

HAQ-DI (0–3), mean (SD)

0.82 (0.67)

0.70 (0.67)

0.96 (0.64)

0.0629

SF-36 PCS (0–100), mean (SD)

33.70 (11.29)

34.63 (10.98)

32.68 (11.66)

0.4099

SF-36 MCS (0–100), mean (SD)

49.15 (10.94)

49.23 (11.17)

49.06 (10.82)

0.9413

HRCT-determined disease extent, mean (SD)

    

 Maximum fibrosis score (0–4)

1.99 (1.05)

1.96 (1.07)

2.02 (1.03)

0.7700

 Maximum honeycombing (0–4)

0.40 (0.58)

0.42 (0.54)

0.37 (0.62)

0.9592

 Maximum ground-glass opacity (0–4)

0.73 (0.76)

0.73 (0.71)

0.72 (0.83)

0.7101

Visual maximum fibrosis score, n (%)

   

0.2007

 0 %

7 (7.69)

4 (8.33)

3 (6.98)

 

 1–25 %

25 (27.47)

15 (31.25)

10 (23.26)

 

 26–50 %

25 (27.47)

9 (18.75)

16 (37.21)

 

 51–75 %

30 (32.97)

19 (39.58)

11 (25.58)

 

 76–100 %

4 (4.40)

1 (2.08)

3 (6.98)

 

Goh and Wells unadjusted stratification for lung involvement (consensus of 3 readers), n (%)

   

0.5298

 <20 %

38 (44.71)

22 (47.83)

16 (41.03)

 

 >20 %

47 (55.29)

24 (52.17)

23 (58.97)

 

 Goh’s adjusted minimal disease, n (%)

20 (21.98)

8 (17.02)

12 (27.27)

0.3540

 Goh’s adjusted extensive disease, n (%)

71 (78.02)

39 (82.98)

32 (72.73)

 

CAD scores

    

 QILD WL, mean (SD)

34.71 (15.67)

34.96 (16.95)

34.44 (14.35)

0.8771

 QILD ZM, mean (SD)

58.84 (20.94)

58.53 (21.33)

59.19 (20.75)

0.8833

 QLF WL, mean (SD)

9.80 (9.83)

10.11 (10.60)

9.47 (9.02)

0.7591

 QLF ZM, mean (SD)

26.44 (21.82)

25.23 (21.44)

27.77 (22.40)

0.5851

  1. FVC forced vital capacity, DLCO diffusing capacity for carbon monoxide, MRSS modified Rodnan skin thickness score, BDI Baseline Dyspnea Index, HAQ-DI Health Assessment Questionnaire Disability Index, PCS Physical Component Score, SF-36 36-item Short Form Health Survey, MCS Mental Component Score, HRCT high-resolution computed tomography, CAD computer-aided diagnosis, QILD quantitative assessment of total extent of interstitial lung disease, QLF quantitative percentage of lung fibrosis, ZM zone of maximal involvement, WL whole lung, SD standard deviation, SSc systemic sclerosis, CYC cyclophosphamide
  2. a p < 0.05